This test is most useful if any of these apply to you.
A large blood pressure drop when you stand, severe slowing of digestion, and loss of sweating can occur together when your autonomic nervous system is failing. An immune attack on the nerve relay stations is one possible cause. This antibody can help identify it, especially when several automatic functions are affected.
Ganglionic acetylcholine receptor antibody testing is an established diagnostic aid for suspected autoimmune autonomic ganglionopathy. Its usefulness depends on the symptoms and examination findings that led to testing. An isolated positive result carries much less weight.
The autonomic nervous system helps regulate blood pressure, heart rate, digestion, bladder emptying, sweating, and pupil size. Many of its signals pass through clusters of nerve cells called ganglia. At these relay stations, acetylcholine carries a signal from one nerve cell to receptors on the next.
Ganglionic AChR antibodies bind receptors containing a piece called the alpha-3 subunit. Experiments with antibodies purified from the blood of people with AAG show that they can reduce receptor function in cultured nerve cells. Other cell experiments show loss of receptors from the cell surface. These laboratory findings help explain how the antibodies can interrupt nerve signaling.
This test measures receptor-binding antibodies in serum using radioimmunoprecipitation. Serum is the liquid left after blood clots. The assay measures binding to receptors extracted from cells; it does not directly measure the antibody's effect on living nerves. Autonomic function tests provide that clinical context.
Autoimmune autonomic ganglionopathy is usually shortened to AAG. It can develop quickly or progress more slowly, and it can disrupt several automatic functions at once. Common features include:
Other illnesses can coexist with AAG. A Japanese study of 179 people who tested positive using a research assay for alpha-3 and beta-4 receptor antibodies also reported sensory symptoms, brain-related symptoms, hormone disorders, other autoimmune diseases, and tumors. That assay differs from this receptor-binding test, and the findings do not establish that this antibody caused every accompanying problem.
Higher antibody levels are more strongly associated with severe autonomic failure, but the relationship has exceptions. Some people with substantial autonomic impairment have low levels, and some with high levels have little impairment.
| Who Was Studied | What Was Examined | What They Found |
|---|---|---|
| 157 people with various autonomic disorders, plus control groups | Serum receptor-binding antibodies in different clinical groups | Antibodies were found in 41% of the 46 people with unexplained or cancer-associated autonomic neuropathy. None of 133 healthy controls tested positive, though some people with other autonomic disorders did. |
| 289 antibody-positive people with autonomic testing | Antibody level and measured autonomic impairment | Higher levels were more closely associated with severe failure. Low levels did not reliably distinguish people with autonomic failure from those without it. |
| 95 antibody-positive people at a neurology referral center | How often a positive result accompanied AAG | Only 22% had AAG. Their median antibody level was about twice that of people without autonomic manifestations. |
A substantial result together with a matching pattern of autonomic failure strongly supports an immune cause. A negative result still leaves room for AAG: the standard antibody assay detects only about half of clinically diagnosed acute or subacute cases.
Low-level receptor-binding antibodies have been found in people with celiac disease or lupus who lacked clear autonomic failure. Their presence may reflect a broader autoimmune response, but a positive result alone cannot establish why you have symptoms.
Several Japanese studies examined serum antibodies to the alpha-3 and beta-4 receptor pieces separately using a research method called LIPS. Its measurements and positivity rates are not interchangeable with this radioimmunoprecipitation test. Those studies reported the following associations:
These findings support investigating immune mechanisms in some autonomic and digestive disorders. They do not establish these assays as general screening tests for those conditions or prove that an antibody-positive person will benefit from immune treatment.
Some cases of AAG occur as part of a cancer-associated immune response. Reported tumors include lung cancer and thymoma. A thymoma develops in the thymus gland in the chest.
The antibody alone is a limited cancer predictor. In the 95-person referral cohort, only two new cancers were diagnosed after antibody detection. Cancer risk assessment therefore depends on the neurological syndrome, other antibody findings, medical history, and symptoms. A low positive by itself does not justify an extensive cancer search.
Antibody changes sometimes accompany recovery, but they can also diverge from symptoms. In a three-person conference report, two people had rising levels after immune treatment was withdrawn without a return of severe autonomic failure, although some bowel, bladder, and pupil abnormalities remained or increased. A later UK study with long-term follow-up found that antibody levels reflected impairment at disease onset better than changes during follow-up. Symptoms and measured autonomic function remain central to treatment decisions.
Evidence-backed interventions that affect your Acetylcholine Receptor Ganglionic Antibody level
Acetylcholine Receptor Ganglionic Antibody is best interpreted alongside these tests.